Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 9.79% | 424.33 | 0.0% | $8556.04m | |
| BNTX | BioNTech SE | 16.31% | 409.19 | 0.0% | $1502.83m | |
| NVAX | Novavax, Inc. | 21.93% | 229.92 | 79.8% | $808.62m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -1.66% | 10.64 | 0.7% | $743.78m | |
| AMGN | Amgen, Inc. | -6.09% | 229.21 | 1.3% | $475.94m | |
| BIIB | Biogen, Inc. | -0.14% | 337.54 | 1.7% | $453.20m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.67% | 201.39 | 1.9% | $423.27m | |
| GILD | Gilead Sciences, Inc. | -0.40% | 69.55 | 1.0% | $408.62m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.27% | 593.98 | 2.7% | $324.29m | |
| ILMN | Illumina, Inc. | 0.45% | 500.65 | 3.5% | $261.30m | |
| NTLA | Intellia Therapeutics, Inc. | -1.24% | 137.07 | 2.3% | $190.45m | |
| CRSP | CRISPR Therapeutics AG | 0.96% | 122.59 | 0.6% | $136.47m | |
| SGEN | Seagen Inc. | 2.60% | 162.30 | 5.8% | $134.14m | |
| EXAS | EXACT Sciences Corp. | 1.82% | 106.11 | 18.1% | $130.59m | |
| BGNE | BeiGene Ltd. | 1.27% | 345.78 | 1.3% | $130.55m |
Company Profile
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.